Professional Analysts at Cowen & Co. Reconfirmed their “Buy” rating for Autodesk (ADSK). The TP is $130.0; Vertex Pharmaceuticals (VRTX) Shorts Decreased By 2.24%

February 15, 2018 - By Dolores Ford

Among 27 analysts covering Autodesk Inc. (NASDAQ:ADSK), 18 have Buy rating, 3 Sell and 6 Hold. Therefore 67% are positive. Autodesk Inc. has $150.0 highest and $9 lowest target. $114.96’s average target is 1.12% above currents $113.69 stock price. Autodesk Inc. had 109 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Autodesk, Inc. (NASDAQ:ADSK) has “Overweight” rating given on Monday, February 22 by Barclays Capital. The firm has “Buy” rating by Rosenblatt given on Wednesday, October 7. KeyBanc Capital Markets maintained the shares of ADSK in report on Friday, August 25 with “Overweight” rating. Robert W. Baird maintained it with “Outperform” rating and $62 target in Monday, March 28 report. The firm earned “Buy” rating on Sunday, October 8 by RBC Capital Markets. As per Thursday, December 8, the company rating was upgraded by Rosenblatt. Cowen & Co maintained the shares of ADSK in report on Friday, August 26 with “Outperform” rating. Barclays Capital maintained the stock with “Buy” rating in Tuesday, November 21 report. The firm has “Sell” rating by Zacks given on Wednesday, September 2. The stock of Autodesk, Inc. (NASDAQ:ADSK) has “Buy” rating given on Wednesday, November 29 by Credit Suisse.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had a decrease of 2.24% in short interest. VRTX’s SI was 4.29 million shares in February as released by FINRA. Its down 2.24% from 4.39 million shares previously. With 1.23M avg volume, 4 days are for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s short sellers to cover VRTX’s short positions. The SI to Vertex Pharmaceuticals Incorporated’s float is 1.74%. The stock increased 1.50% or $2.355 during the last trading session, reaching $159.615. About 555,493 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 15, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. State Of Wisconsin Board invested 0.1% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The New York-based Cannell Peter B Inc has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sivik Global Health Ltd Llc accumulated 50,000 shares. Us Bankshares De accumulated 0% or 7,197 shares. United Automobile Association has 0.07% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 165,044 shares. Hanseatic Management Ser accumulated 0.81% or 4,673 shares. Green Valley Investors Lc invested in 0.96% or 129,744 shares. Acadian Asset Limited Co stated it has 198,193 shares or 0.13% of all its holdings. Princeton Portfolio Strategies Gp Ltd Liability Company reported 1,930 shares. Pennsylvania owns 1,445 shares. Robeco Institutional Asset Mngmt Bv has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 313,427 are owned by Hsbc Public Ltd Com. Clearbridge reported 0% stake. Wilbanks Smith And Thomas Asset Mgmt Ltd Liability Corporation holds 3,433 shares or 0.04% of its portfolio. Valley Advisers invested in 0.01% or 151 shares.

Since August 31, 2017, it had 0 insider purchases, and 37 insider sales for $109.10 million activity. $580,304 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Chodakewitz Jeffrey. $960,960 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit on Tuesday, January 23. 1,796 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $287,360 were sold by ALTSHULER DAVID. LEIDEN JEFFREY M sold $17.67M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, December 11. Shares for $334,232 were sold by SMITH IAN F. 777 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $116,511 were sold by Graney Thomas. Parini Michael had sold 3,450 shares worth $600,680 on Thursday, February 1.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by RBC Capital Markets on Wednesday, January 31. Barclays Capital upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, July 19 to “Overweight” rating. On Tuesday, February 13 the stock rating was maintained by Credit Suisse with “Outperform”. The rating was maintained by Piper Jaffray with “Buy” on Thursday, October 26. The rating was upgraded by Needham on Friday, June 23 to “Buy”. As per Tuesday, December 1, the company rating was initiated by Stifel Nicolaus. The firm earned “Buy” rating on Wednesday, July 19 by Jefferies. The stock has “Buy” rating by Cowen & Co on Monday, September 25. The firm has “Buy” rating by Maxim Group given on Wednesday, January 31. The firm has “Buy” rating given on Thursday, February 1 by Leerink Swann.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $40.42 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 153.48 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Analysts await Autodesk, Inc. (NASDAQ:ADSK) to report earnings on March, 1. They expect $-0.34 earnings per share, up 39.29% or $0.22 from last year’s $-0.56 per share. After $-0.42 actual earnings per share reported by Autodesk, Inc. for the previous quarter, Wall Street now forecasts -19.05% EPS growth.

Investors sentiment increased to 1.42 in Q3 2017. Its up 0.23, from 1.19 in 2017Q2. It is positive, as 36 investors sold Autodesk, Inc. shares while 132 reduced holdings. 61 funds opened positions while 177 raised stakes. 206.38 million shares or 1.05% more from 204.24 million shares in 2017Q2 were reported. Sg Americas Llc reported 0.03% stake. Moreover, Glaxis Capital Mgmt Llc has 1.71% invested in Autodesk, Inc. (NASDAQ:ADSK). Boothbay Fund Mgmt Limited Com holds 0.44% or 23,786 shares in its portfolio. Ftb Advisors owns 437 shares or 0% of their US portfolio. Riverhead Limited Liability Com holds 2,912 shares or 0.02% of its portfolio. 148,073 are owned by Millennium Ltd Liability Company. Victory Cap Mngmt owns 3,617 shares for 0% of their portfolio. Pacific Heights Asset Mngmt Ltd Liability Corp holds 1.16% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK) for 108,000 shares. First Long Island Invsts Lc has 0.05% invested in Autodesk, Inc. (NASDAQ:ADSK). Ballentine Ptnrs Limited Liability Corporation accumulated 0.03% or 5,007 shares. British Columbia Investment holds 112,308 shares. Mycio Wealth Prns Ltd Liability Co holds 2,500 shares or 0.03% of its portfolio. Blackrock holds 0.1% in Autodesk, Inc. (NASDAQ:ADSK) or 16.81 million shares. Nordea Investment Mgmt Ab reported 0% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Aperio Grp Ltd Liability invested in 116,495 shares or 0.07% of the stock.

Autodesk, Inc. operates as a design software and services firm worldwide. The company has market cap of $25.04 billion. It operates through Architecture, Engineering, and Construction; Manufacturing; Platform Solutions and Emerging Business; and Media and Entertainment divisions. It currently has negative earnings. The firm offers AutoCAD, a professional design, drafting, detailing, and visualization software; and AutoCAD LT, a professional drafting and detailing software; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Revit software for building information modeling.

Since August 28, 2017, it had 0 buys, and 5 insider sales for $6.74 million activity. Shares for $64,328 were sold by Di Fronzo Pascal W on Monday, October 2. $169,230 worth of Autodesk, Inc. (NASDAQ:ADSK) shares were sold by BEVERIDGE CRAWFORD W. $1.02M worth of Autodesk, Inc. (NASDAQ:ADSK) shares were sold by Blum Steven M. NORRINGTON LORRIE M also sold $2.78 million worth of Autodesk, Inc. (NASDAQ:ADSK) shares. Anagnost Andrew also sold $2.71M worth of Autodesk, Inc. (NASDAQ:ADSK) shares.

The stock increased 3.43% or $3.77 during the last trading session, reaching $113.69. About 1.44M shares traded. Autodesk, Inc. (NASDAQ:ADSK) has risen 91.08% since February 15, 2017 and is uptrending. It has outperformed by 74.38% the S&P500.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>